Garcinia cambogia e medicamentos para a obesidade: uma previsão das interações medicamentosas

Abstract

Objective: To characterize the possibilities of drug interactions of therapeutic ingredients of Garcinia cambogia. Method: This study presents a research methodology that employs molecular modeling to analyze how active ingredients of Garcinia cambogia interact with medications. Platforms (Swiss ADME and Protox-II) are used to predict metabolism, toxicity, and potential drug interactions, aiming for the safe use of the plant in medical treatments. Results: The inhibitory capacity of components of Garcinia cambogia on cytochrome P450 is highlighted, which may affect the treatment of obesity comorbidities. Furthermore, the potential of Oxigutiferones I and K to influence neurotransmission and gene expression is highlighted according to prediction software analyses. This interaction between components of Garcinia cambogia and the enzyme CYP3A4 can alter the effects of medications used by obese patients, potentially enhancing both desired and adverse effects. It is crucial to monitor these interactions to avoid complications, such as serotonin syndrome or exacerbated anti-androgenic effects. Conclusion: Attention is drawn to the risks of drug interactions in obese patients using Garcinia cambogia, emphasizing the importance of careful pharmacological choices and medical monitoring.